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Objectives
• Describe emerging trends in infectious disease
• Recognize epidemiologic risk factors for emerging and resurgent
infectious disease
• Develop a differential diagnosis that includes appropriate
infectious disease

Unanticipated Epidemics since 1980
• Staphylococcus aureus toxic
shock
S aureus USA 300
AIDS
West Nile virus
Lyme disease
Avian influenza
Severe acute respiratory
syndrome (SARS)
• Middle Eastern respiratory
syndrome (MERS)
•
•
•
•
•
•

Legionnaires' disease
Measles
Ebola
Cryptosporidiosis
H1N1 influenza ("swine flu")
Iatrogenic fungal meningitis
Clostridium difficile NAP1 strain
Norovirus ("cruise-ship
dysentery")
• Anthrax bioterrorism
•
•
•
•
•
•
•
•

Recent and Current Epidemics
• World Wide
•
•
•
•
•
•
•
•

• In the US and California

Zika Virus
Yellow Fever
Ebola
Dengue
Chikungunya
Enterovirus
Influenza
Middle Eastern Respiratory
Syndrome

•
•
•
•
•
•
•
•

Zika Virus
West Nile Virus
Meningitis
Multi Drug Resistant Organisms
Clostridium difficile Infections
Community Acquired Pneumonia
Influenza
Vaccine Preventable Illness
• Measles, others

Viral Hemorrhagic Fevers
• From one of 4 families
•
•
•
•

Flaviviridae (Dengue)
Bunyaviridae (Hanta)
Arenaviridae (Lassa)
Filoviridae (Ebola)

• All but Dengue may be spread by aerosol
• All cause increased vascular permeability and in severe cases
systemic inflammatory response, shock, organ failure and death.
• Mortality ranges from 10% (Dengue) to 90% (Ebola)

Zika Virus
• Originally discovered in the Zika forest of Entebbe, Uganda in primates in 1947.
Sporadic small outbreaks in 2007, 2013 and 2014 in equatorial region. Brazil
January 2016, developing pandemic.
• An arbovirus (arthropod borne) in the genus Flaviviridae.
• Dengue, yellow fever, WNV, St. Louis encephalitis, Japanese encephalitis all in the same
genus

• ssRNA about 11k bases, 40 microns in size and is enveloped
• Enters host cell via membrane fusion, replicating in the cytoplasm and is shed
via budding
• Humans are one of many hosts. Zika can reproduce in arthropods and
vertebrates
• Vector is the Aedes mosquito, but is also sexually transmitted and crosses the
placenta (in utero transmission)

Current Zika active transmission as of 8/2/16

US Zika cases as of 8/3/16

US range of Aedes mosquitos

Source: CDC

Zika vector: Aedes mosquitos
• Aedes aegypti
•
•
•
•

Tropical, sub-tropical and somewhat in temperate climates
Prefer to feed on humans, and will feed during the day
Aggressive: will follow you inside your house
Have developed localized resistance to several insecticides

• Aedes albopictus
• Tropical and sub-tropical, but can live at a broader range of temperate climates than
aegypti
• Will feed on animals or humans
• Aggressive, generally hang out around where humans live.

• Both like small sheltered containers to lay eggs
• Eggs are hearty and can withstand desiccation for one year, but perish at <10°C

Zika Signs and Symptoms
• Incubation period of 3-12 days, 80% of infections go unnoticed.
• Most are asymptomatic, but if symptomatic will be so for 2-7 days
• Viremia is high in first week of illness and virus is shed for several days after
resolution of symptoms.

• Rash, fever, and arthralgia are the main sypmtoms
• Fine, diffuse maculopapular rash including palms and soles
• Arthralgia predominates in small joints of hands and feet
• Myalgias and HA may also occur

• Differential diagnosis is broad but should include other arboviruses
common in area of travel
• Dengue, chickungunya, etc

Zika Rash

emedicine.medscape.com
/article/2500035-clinical

Diagnostic Studies for Zika
• Lab
• Reverse transcriptase polymerase chain reaction (RT-PCR) will become
positive during the initial week.
• After the 1st week anti-Zika IgM by ELISA will be positive but has cross
reactivity with other flavivirus’
• Individual flavivirus antibody can be tested by plaque reduction
neutralization tests (PRNT)
• CDC recommends urine or serum RT-PCR, if neg, then IgM with PRNT

• Urine samples remain positive for RT-PCR for at least two weeks longer than
serum.

Complications and Treatment of Zika
• Really only a risk in pregnancy
• Microcephaly incidence increased 20 fold in Brazil since outbreak
• Also causes ophthalmologic abnormalities

• Guillian-Barre Syndrome (GBS) has been reported following Zika
• Current treatment consists of supportive therapy
• Avoid NSAIDS due to possible increased risk of bleeding (like Dengue)
• IvIg for severe GBS

• In those who are pregnant careful monitoring and evaluation of the fetus
is indicated
• US for microcephaly or intracranial calcifications
• Amniotic fluid testing for Zika

Prevention of Zika
• Control of vectors
•
•
•
•

DEET, mosquito nets, permethrin, long sleeves and pants
Reduce standing water, insecticide spraying,
Genetically modified mosquitos: offspring are incapable of survival1
Chinese have infected mosquitos with wolbachia bacteria which causes
infertility of female if from mating, or the offspring if female is infected from
other means2

• Avoid intercourse or use condoms for 28 days after illness or travel
• Wait 8 weeks to attempt to conceive, men 6 months.
• Vaccine in development
• One in Phase 1 trial, others developing

1. medscape.com/viewarticle/867009. 2. medscape.com/viewarticle/866928

Chikungunya Virus (CV)
• Originally discovered in 1952 in Tanzania, Africa
• Name means “to be bent over” in Swahili. Known as “buka-buka”
in the Congo, which means “broken-broken”, probably due to the
debilitating arthralgias caused by the virus
• Arbovirus in the Togaviridae family, alpha virus genus (different
family from Dengue and Zika)
• Others in the same genus and family: WEE, EEE, Ross river virus

• ssRNA virus, about 11k bases, with envelope. Cell entry is under
study

Chikungunya Virus (CV)
• Characterized by outbreaks and long periods of quiescence
• Outbreak in the Americas since June 2014
• 2014 – 2811 cases in continental US and 4710 in territories
• 12 locally transmitted cases in FL, almost all locally transmitted in territories

• 2015 – 896 cases in continental US, and 237 in territories
• 1 locally transmitted in TX, almost all locally transmitted in territories

• 2016 – 59 cases in continental US, and 99 in territories
• No locally transmitted cases in continental US, almost all locally transmitted in
territories

Current or previous CV as of 4/22/2016

Image source: CDC

Chikungunya in the US as of 8/9/16

Image source: CDC

Range of Aedes mosquitos US

Chikungunya Virus (CV)
• Major vector is Aedes aegypti, but CV mutated in 2006 to a form
that could be transmitted by Aedes albopictus.
• Humans are the major reservoir during epidemics, but birds,
primates, and rodents may be also in quiescent periods.
• Travel to endemic areas is the major risk factor, and likely cause
for increased cases in US and Europe
• Clinical illness occurs in 40-85% of infections
• Clinical infection overlaps with Dengue and co-infection can occur
• 3-7 day incubation period, not usually a prodrome

Chikungunya Virus (CV) signs and symptoms
• Abrupt onset of high fevers (102-105°F) with shaking chills lasting 2-3
days
• May defervesce for 4-10 days and then have a recurrence of fever for 1-2 days
(saddle back fever)

• Pharyngitis, conjunctivitis and photophobia occur
• Severe arthralgias/myalgias and a rash are common
• Arthralgias are more common in the small joints, and often involve more than
10 joint groups, incapacitating the patient
• Patients typically lie still in a flexed posture, avoiding movement
• Hips are usually spared, but the axial skeleton is usually involved
• Most have a complete resolution in 1-2 weeks, but some 30% develop chronic
debilitating joint pain lasting for years

Chikungunya Virus (CV)
• Rash

• Flushed appearance of face and trunk
• Diffuse erythematous maculopapular rash involving trunk and extremities,
sometimes including palms and soles
• Gradually fades, sometimes with petechia, xerosis, hypermelanosis or
desquamation

• Mortality is about 10%

• More common in elderly, young and those with co-morbidities

• CV, respiratory and neurologic co-morbidities predispose to severe infection

• Not as neuroinvasive as other alpha viruses

• Neurologic disease is more common in neonates.
• Vertical transmission does occur

Chikungunya Virus (CV)
• Diagnostic Criteria
• Fever and arthralgias with history of travel to endemic area
• Dengue, Malaria, other tropical diseases excluded
• Lab
• CV specific IgM, IgG via ELISA labs take 5-7 days to become positive
• At 2-3 days viremia is high, culture may be positive if test available
• CDC offers a reverse transcriptase polymerase chain reaction (RT-PCR) test

• Treatment
• Generally supportive, NSAIDS. Caution with ASA (bleeding risk)
• Anti-virals and steroids are not effective

Dengue
• Originated in primates but moved to humans
• Most common arbovirus in humans
• Earliest outbreak was 1635 in west indies but similar illness recorded in
China CE 265-420, associated with flying insects near water
• 1780 outbreak in North America
• Became much more common after WWII vector spread with cargo
• Vector control very effective at limiting until 1970s, resurgent since 1980s.

• 50-100 million cases/year worldwide
• 500k cases of dengue hemorrhagic fever (DHF) annually, 22k deaths
• About 250 cases/year in US; FL 2010, TX 2005

Dengue
• ssRNA virus about 11k bases, enveloped
• Enters primarily Langerhans cells and WBC via membrane fusion
• Reproduces in the cytoplasm of dendritic cells, hepatocytes, and
endothelial cells and is shed by budding
• Four distinct serotypes

• Full immunity derived to serotype after infection, partial immunity to other
• Serotypes co-exist, infection with more than one, and infection of one after
another is associated with more severe disease (i.e. DHF).

• Humans are the reservoir, though some primates can serve as hosts
without developing disease. The virus can also replicate in the vector.
• Aedes mosquitos are the vector, and are not affected by the virus.

Dengue
• Viremic host must coexist with sufficient number of vectors for
outbreak to occur
• Follows two patterns: epidemic, and hyperendemic (ongoing)
• Patient is viremic one day before symptoms and until symptoms
resolve (5-7 days)
• Incubation period 3-14 days, average is 4-7 days
• Initial infection is asymptomatic 50-90%, or may present as a nonspecific viral illness
• Usually self-limited

Dengue Signs and Symptoms
• May be asymptomatic, particularly if child <15 yrs old
• Recovery usually within 7-10 days

• Dengue Fever

Reddish mottling of skin and facial flushing
Aching pain all over, mostly neck and back (“breakbone fever”)
Fever begins day 3 of illness and persists 5-7 days
Leukopenia, lymphopenia and thrombocytopenia are common
High fever (106°F). May have “saddleback fever”: 1-2 days of fever,
defervescence for a day, Then recurrence of fever.
• 33% of patients may have mild hemorrhagic symptoms

•
•
•
•
•

• Petechiae, gingival bleeding, positive tourniquet test (>20 petechiae after BP cuff)

• Rarely fatal
• Treatment is symptomatic and supportive

Dengue Signs and Symptoms
• Dengue Hemorrhagic Fever (DHF)
•
•
•
•
•
•
•
•

Almost always occurs in those with prior exposure to Dengue
Primarily occurs in children but can affect anyone
Biphasic fever, when recurs will have septic shock and hemorrhagic sx
Increasing HCT (from plasma leakage into tissues) and low albumin, atypical
lymphocytes, transaminases elevated, thrombocytopenia
GI bleed or other sites due to profound capillary fragility
Ascites and/or pleural effusions due to increased capillary permeability
DIC and severe metabolic acidosis may occur
Mortality
• Treated 2-5%, untreated 50%.

Dengue diagnostic studies
•
•
•
•
•
•
•
•

CBC
LFT
PT/INR, PTT, DIC panel if available
UA
Guiac
Dengue virus IgM/IgG titer with x4 increase
PCR for viral RNA is available at reference laboratories
Serial US for pleural effusions shows DHF before labs are pos.

Dengue Treatment
• Usually self limited
• Supportive
• Avoid NSAIDS and ASA due to bleeding risk
• Steroids are not beneficial
• DHF should be treated in ICU
• Careful attention to fluid balance and hemorrhage

Ebola Virus
• Outbreak June 2014 – December 2015 in West Africa
• Largest Ebola outbreak in history
• 28,652 infected; 11,325 deaths
• 4 cases in US: two imported, two locally acquired

• Discovered in 1976 in Congo, near the Ebola river
• Natural reservoir is unknown, likely bats and primates
• Bats can have high viremia and not get sick, live virus present in stool
• Infected animals killed for consumption (bush meat) may contain virus

• Body fluids of infected persons are highly contagious

Ebola
• Filamentous form, enveloped, negative stranded RNA
• 5 species
• 4 cause disease in humans, 1 in animals only
• Dogs can be infected

• Relative sparing of children
• Can reproduce in all tissues
• Predilection for liver, endothelium, and mononuclear phagocytes
• Necrosis is seen in liver, spleen, lymph nodes, kidney, lung and gonads

• May inhibit adequate immune response

Ebola Clinical Course
• Primary exposure
• Travel to endemic area, incubation period 3-8 days

• Secondary exposure
• Human to human contact with infected patient, incubation period up to 21 days

• Sudden onset of
• Fever/chills, HA, myalgias/arthralgias followed quickly by GI symptoms
• Abdominal pain, N/V/D, odynophagia and dysphagia

• Half of patients will have conjunctivitis, mucus membrane/GI bleeding, and
hemorrhage from puncture sites
• May have a maculopapular rash which desquamates in survivors

• Tachypnea is a poor prognostic indicator

Ebola Diagnostic Studies
• Virus can be detected in sweat and urine with one hour turnaround but
is not widely available. Most will have a 24-48 hour turnaround.
• Antigen detection test by ELISA
• IgM and IgG will be positive if patient survives long enough to mount an
immune response.
• Thrombocytopenia and neutropenia are common.
• Various markers of organ function will decline as organ failure occurs.
• No useful imaging tests

Ebola Treatment
• STRICT BARRIER PRECAUTIONS/ISOLATION
• All body fluids contain high numbers of infectious virions

• Supportive
• Replacement of coagulation factors
• Fluids and nutrition

• Survivors will continue to shed virions for several weeks or months
after clinical recovery, which is slow
• Sexual transmission occurs. Unknown how long virus remains in semen after
clinical recovery.

• Vaccines under development

West Nile Virus (WNV)
• Arbovirus in the Flavivirus genus like Japanese encephalitis
• ssRNA with 11k bases, enveloped, enters cell by membrane fusion,
reproduces in the cytoplasm and is shed by budding
• First discovered in 1937 in Uganda, first cases in us in 1999
• Several large outbreaks in the US. About ½ are neuroinvasive
• Since 1999 41762 cases, 18810 neuroinvasive
• 2012: 5674 cases and 256 deaths.
• 22 cases this year in CA, one death as of 8/14/16.

WNV in US and CA

WNV
• Birds are the host and reservoir
•
•
•
•

Non-bird animals and humans are dead end hosts
Dead birds can’t transmit the disease but are a marker of virus presence
Not transmitted animal to person, or person to person
Vertical transmission vector to offspring

• Culex mosquitos are the main vector
• Aedes: VHF
• Anopheles: malaria

Culex mosquito
• Worldwide distribution
• Most common mosquito in us
cities
• Can extend to far north of
temperate zone
• Smaller than Aedes
• No stripes
• Generally dawn/dusk or night
feeder

WNV Signs and Symptoms
• Incubation 2-14 days but can be longer, especially if immune
compromised
• Acute systemic febrile illness (20%)
•
•
•
•

Headache, weakness, myalgia, or arthralgia
Gastrointestinal symptoms
Maculopapular rash
Complete recovery is the rule, sometimes with lingering fatigue

WNV Signs and Symptoms
• Neuroinvasive disease (<1%)
Much more common in persons >50 years old and immunosupressed
10% mortality, mostly for encephalitis and paralysis
Meningitis: fever, HA, nuchal rigidity
Encephalitis: fever, altered mental status (AMS), seizures, focal neurologic
deficits, or movement disorders
• Acute flaccid paralysis:
•
•
•
•

• clinically identical to poliovirus-associated poliomyelitis
• isolated limb paresis or paralysis
• can occur without fever or apparent viral prodrome

WNV Diagnostic Studies
• Serum or CSF IgM for WNV by ELISA, with PRNT to confirm
• Some cross reactivity with other Flavaviridae

• CBC
• Hyponatremia may be seen in encephalitis from SIADH
• CSF shows viral picture
• Elevated protein, lymphocytes, normal glucose

• Brain MRI usually normal but will show damage to basal ganglia,
thalamus, and brainstem in encephalitis or damage to the anterior
spinal cord in paralysis

WNV Treatment
• Supportive and symptomatic
• Many drugs have been tested, but none proven effective
• Monitor for development of neuroinvasive disease
• PREVENTION
• Limit outdoor activity dusk to dawn
• Use repellent, wear long sleeves
• Vector control

Meningococcus
• Neisseria meningitidis
• Encapsulated aerobic gram neg diplococci
• 13 serogroups, but 5 cause 99% of disease

• Current outbreak among MSM in southern CA.
• Natural habitat is human nasopharynx
• ~10% of population is asymptomatic carrier, up to 60% in closed populations

• Transmitted via droplet or directly via close contact
• Disease occurs when new subtype is introduced and there is a
break in the mucosa – viral URI, smoking

Meningococcus
• Incubation is 3-4 days (range 1-10 days)
• Most infections have mild symptoms or subclinical infection
• 10-20% of infections will become meningococcemic
• Organism reproduces rapidly and systemic symptoms occur before
meningitis by 24-48 hours
• Endothelial necrosis, thrombosis, hemorrhage, DIC occur
• Suppurative complications occur

• Meningitis has 10% mortality even if properly treated early
• 40% mortality if meningococcal sepsis occurs with meningitis

Meningococcus workup and treatment
• Septic workup
• CBC, CMP, Lactate, blood cultures, UA, CSF studies
• CT or MRI of brain (elevated ICP common)
• LP shows elevated opening pressure, WBCs, low glucose, elevated protein
• CSF gram stain positive 70-90%
• Rapid PCR for meningococcus is positive even if abx have been started

• Treatment
• Antibiotics (ceftriaxone very effective, higher dose), fluids, admission

• Prognosis
• 10-20% of those that recover will have some form of sequelae

Meningococcus Prevention
• Prevention
• Vaccines available for usual virulent strains
• A, B, C, W, Y

• High risk groups

• Prophylaxis for close contacts in outbreak
• ciprofloxacin for adults
• ceftriaxone for children

Meningococcal Disease in the US

Multi-Drug Resistant Organisms
• Antibiotics in use for 70 years
• Average time in use until resistance: 2-4 years

• Inappropriate or incorrect use 50% of prescriptions
• Viral, fungal organisms, partially treated.
• Pressure to satisfy/Rx

• Use in animals has greatly contributed to resistance
• CDC estimates 2.05 million illnesses and 23k deaths due to
resistant organisms

Multi-Drug Resistant Organisms
• Urgent Category

• Clostridium difficile
• Carbapenem-Resistant
Enterobacteriaceae (CRE)
• Includes Klebsiella and E. coli
• Some resistant to EVERYTHING

• Neisseria gonorrhoeae

• Serious Category
•
•
•
•
•
•
•
•
•
•
•

Acinetobacter
Campylobacter
Candida
Enterobacteriaceae (ESBL)
Enterococcus (VRE)
Pseudomonas
Salmonella (typhus/non-typhus)
Shigella
Staphylococcus aureus (MRSA)
Streptococcus pneumoniae
M. tuberculosis

What can we do?
• Inpatient

• Know what types of drug-resistant
infections are present in your
facility and patients.
• Request immediate alerts from lab
• Alert receiving facility when you
transfer a patient with a drugresistant infection.
• Follow relevant guidelines and
precautions
• Prescribe antibiotics wisely.
• Remove temporary medical
devices such as catheters and
ventilators as soon as possible.

• Outpatient

• Prescribe wisely

• Narrow spectrum
• Appropriate antibiotic

• Use cultures and evidence based
decisions to prescribe antibiotics
• Stand your ground

What is the CDC doing?
• Four core actions
1. Prevent infections
•

Less illness, less antibiotic use.

2. Tracking resistance
•

Identification of risk factors, control
spread

3. Improving Antibiotic Prescribing and
Stewardship
•

Proper use in animals and humans

4. Developing New Drugs and Diagnostic Tests
•

??

Costs about $2 billion to bring new
drug to market. Resistance in 2-4
years. No ROI.

Vaccine Related Disease
• Many parents are reluctant to immunize because of misinformation and
ignorance of diseases prevented by vaccination.
• Resist the urge to become frustrated
• Most research says that parents are talking to you about it because they trust
your opinion.

• CDC website has great parent focused resources about vaccine safety.
• http://www.cdc.gov/vaccines/parents/index.html

• Finally, new law allows schools to refuse to admit unvaccinated children
• Sacramento county, 145 kids sent home 1st day of school 2016

CA Vaccine Preventable Diseases Report 2014
• H. influenzae: 40 cases, none
type b
• Hepatitis A: 142 cases
• Hepatitis B: 108 cases
• Measles: 75 cases
• Meningococcus: 56 cases

• Mumps: 37 cases
• Pertussis: 11,213 cases
• Rubella: 2 cases
(congenital rubella syndrome)
• Tetnus: 4 cases
• Varicella: 41 DEATHS

Most cases in SF bay area and greater LA area.

Summary
•
•
•
•
•
•
•
•

Zika
Chikungunya
Dengue
Ebola
West Nile
Meningitis
Drug Resistant Organisms
Vaccine Preventable Disease
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